Bye bye, Donald Kennedy

Yesterday (June 21), Science editor-in-chief Donald Kennedy announced he was retiring from the journal, after seven years at the helm. AAAS president David Baltimore is leading a search committee for a new candidate. Kennedy has steered Science through some tricky waters, to say the least. The journal published, then retracted, one of Woo-Suk Hwang's linkurl:now-infamous;http://www.the-scientist.com/news/display/36969/ papers on human embryonic stem cell research. In 2002, the journal lin

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Yesterday (June 21), Science editor-in-chief Donald Kennedy announced he was retiring from the journal, after seven years at the helm. AAAS president David Baltimore is leading a search committee for a new candidate. Kennedy has steered Science through some tricky waters, to say the least. The journal published, then retracted, one of Woo-Suk Hwang's linkurl:now-infamous;http://www.the-scientist.com/news/display/36969/ papers on human embryonic stem cell research. In 2002, the journal linkurl:retracted;http://www.the-scientist.com/article/display/21593/ a controversial paper that suggested the recreational drug Ecstasy predisposed users to Parkinson disease, causing some researchers to demand to see the referees' reports. Kennedy also recently penned an "expression of concern" over a linkurl:paper;http://www.the-scientist.com/news/display/52847/ that showed two-cell embryos have distinct cell lineages. But Kennedy was no stranger to hoopla when he took the Science job, having resigned as president of Stanford University after the school became linkurl:enveloped in controversy;http://www.the-scientist.com/article/display/10955/ over indirect costs. During his tenure, Science has received an linkurl:increasing number;http://www.the-scientist.com/article/display/23061/ of submissions, "at a rate of growth rivaling the rate of Chinese economic growth," according to Kennedy. What do you think about Kennedy's tenure at Science? Tell us here.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies